Codetta Bio

What Codetta Bio does

Codetta Bio is a privately held life-sciences instrumentation company founded in 2020 and headquartered in Morrisville, North Carolina, that develops and commercializes a multi-omic analysis platform for translational research and clinical diagnostics markets. Its flagship product, the Concerto System, integrates digital PCR, real-time PCR (qPCR), and immunoPCR on a microbead-based capture architecture, enabling simultaneous quantification of proteins, DNA, and RNA from a single sample in approximately 3 hours with up to 20-plex multiplexing, sub-pg/mL sensitivity, an 8-log dynamic range, and a maximum throughput of 24 samples per run. The platform is supported by a recurring consumables franchise — Prelude Chips and Prelude Kits (6-plex, 12-plex, and 20-plex configurations) — and a fee-for-service laboratory offering called Sonata Services with four tiers ranging from standard cytokine plus nucleic acid panels to fully customized 6-plex biomarker combinations.

Codetta Bio commercializes the Concerto System through a hybrid go-to-market model combining direct enterprise sales, a 12-month Streaming Service subscription (instrument plus monthly consumables), and a 3-12 month Easy-Lease program targeting mid-market customers. The company sells into translational research (vaccine and immunogenicity work, cell and gene therapy characterization, neuroscience) and clinical diagnostics development (oncology biomarker validation, liquid biopsy, companion diagnostics), supported by a Technology Access Program that recruits pilot customers ahead of full commercial deployment. Distribution and demand generation are driven primarily by participation in major industry conferences (AACR, AGBT, EACR, Swiss Biotech Day, BayO Connect), content marketing, and a newly built global commercial leadership team covering the US, Asia, Middle East, and Africa.

The company is backed by Anzu Partners (lead investor), Genoa Ventures, and VC23 LLC following a $15M Series A in April 2022 and an approximately $12.28M round in June 2024, supplemented by a $2M North Carolina Collaboratory grant awarded jointly with North Carolina Central University in November 2022. Co-founder J. Michael Ramsey (member of the National Academy of Engineering; 165 issued and 15 pending patents) anchors the underlying IP estate. Codetta Bio transitioned from its Technology Access Program to full commercial production of the Concerto System at AGBT 2026, alongside the launch of the Prelude Cytokine Panel and Prelude Neuroscience Panel, and is currently pre-revenue or in early revenue ramp as of the most recent reporting.

Name

Codetta Bio

Legal name

Codetta Bio

Website

https://codettabio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Codetta Bio develops the Concerto multi-omic analysis platform, integrating digital PCR, qPCR, and immunoPCR to simultaneously detect proteins, DNA, and RNA from a single sample for translational research and clinical diagnostics customers.

Ownership category

akta.pro rank

Product category

Multi-Omic Life Sciences Instrumentation

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Multi-omic analysis
• Digital PCR instruments
• Biomarker detection assays
• Life sciences consumables
• Translational research platforms

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Concerto Instrument Sales: Direct sales of the Concerto multi-omic analysis instrument to research laboratories and biopharma companies. Offered through one-time purchase, 12-month streaming subscription with consumables, or flexible 3-12 month lease arrangements.
2. Prelude Consumables: Recurring revenue from Prelude Chips and Prelude Kits (protein quantification and multi-omic configurations) used with the Concerto System. Consumables are delivered monthly under the streaming service model.
3. Sonata Services: Fee-for-service laboratory analysis where Codetta Bio's team performs multi-omic analysis on customer samples. Four service tiers from basic omics analysis to fully customized 6-plex panels.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Codetta Bio develops and sells the Concerto™ System, a multi-omic analysis instrument that combines digital PCR, real-time PCR, and immunoPCR on a microbead-based platform to simultaneously quantify proteins, DNA, and RNA from a single sample in approximately 3 hours. The company also sells Prelude Chips and Prelude Kits as recurring consumables (in 6-, 12-, and 20-plex configurations) and offers Sonata Services for outsourced multi-omic sample analysis across four service tiers. The platform is positioned for translational research and clinical diagnostics development markets requiring high-sensitivity, high-multiplex biomarker detection.

Product overview

Codetta Bio offers a unified multi-omics platform combining hardware, consumables, and services. The core Concerto System instrument integrates digital PCR, real-time PCR, and immunoPCR to analyze proteins, DNA, and RNA from a single sample in a 3-hour run. This platform is supported by Prelude Chips and Prelude Kits (available in 6-plex, 12-plex, and 20-plex configurations) as consumables. Service offerings include Sonata Omics Analysis, Sonata Duo Immune Analysis, Sonata Tailored Omics Analysis, and Sonata Custom Analysis for outsourced sample processing. Upcoming Prelude Cytokine and Neuroscience Panels expand the assay menu for specific research applications. The Technology Access Program provides early access to the platform for proof-of-concept studies.

Differentiator

Problem solved

Functional benefit

Brands

• Sonata Services: Harmonized multi-omic analysis services combining nucleic acid and protein analysis.
• Concerto™ System
• Prelude Chips and Kits

Products and services

• Concerto™ System Flagship multi-omic analysis instrument that combines digital PCR, real-time PCR, and immunoPCR technologies to simultaneously measure proteins, DNA, and RNA from a single sample in approximately 3 hours. Processes up to 24 samples across three Prelude chips with an 8-log dynamic range and up to 20-plex multiplexing capability. Targets translational research and clinical diagnostics development customers.
• Prelude Chips

Quantifiable outcome

• 8-log dynamic range enabling precise quantification across low and high target concentrations without serial dilutions
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Dr. Jay ManikandancoreOthers · 9 December 2025Appointed as regional commercial leader to lead Asia, Middle East, and Africa markets for the Concerto System, supporting global adoption and regional market expansion.
• Jay GerlachcoreOthers · 9 December 2025Appointed to oversee global marketing operations, supporting the full commercial launch and increasing market demand for multi-omic solutions.
• North Carolina Central UniversitycoreStrategic or Co-development Partner · 8 November 2022Codetta Bio and North Carolina Central University received a $2 million grant from the North Carolina Collaboratory to develop an integrated platform for detection and assessment of COVID-related health issues, including long-COVID. This collaboration supports joint research and clinical care enhancement.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Standard BioTools: Standard BioTools (formerly Fluidigm) markets mass cytometry, imaging mass cytometry, and microfluidic multi-omic instruments for translational and clinical research. Like Codetta, it pursues high-multiplex protein/nucleic acid analysis from limited samples with proprietary microfluidics, targeting academic and biopharma translational labs.
• Olink Holding: Olink provides proximity extension assay (PEA) technology for high-throughput targeted proteomics, widely used in translational research, biomarker discovery, and pharma drug development. It is a direct competitor to Codetta's multi-analyte protein detection workflow and shares the same customer base of translational research and biopharma groups.
• Quanterix: Quanterix develops ultra-sensitive single-molecule array (Simoa) immunoassay technology for sub-pg/mL protein detection, primarily in neurology and immuno-oncology. It is directly comparable to Codetta on the sensitivity and biomarker dimensions and serves overlapping translational research customers.
• Meso Scale Diagnostics: MSD provides electrochemiluminescence-based multiplex immunoassay platforms used widely in pharma clinical trials and translational research. It competes with Codetta on multiplex protein quantification, dynamic range, and biopharma customer relationships, and is a key incumbent in immuno-oncology biomarker work.
• 10x Genomics: 10x Genomics offers single-cell and spatial multi-omic platforms (Chromium, Visium, Xenium) combining gene expression and protein measurements. It is a direct comparable to Codetta in the multi-omic, translational research market and competes for similar biopharma and academic budgets on the spatial and multi-analyte axis.
• Luminex (DiaSorin): DiaSorin's Luminex franchise provides xMAP bead-based multiplex assay platforms for protein and nucleic acid detection. The bead-based architecture and translational/biopharma customer overlap make it a directly comparable peer to Codetta's microbead-based multi-omic workflow.
• Nanostring Technologies: Nanostring (now part of Bruker) provides spatial multi-omic and gene expression platforms (GeoMx, CosMx, nCounter) used in translational research and clinical development. It overlaps with Codetta on the spatial multi-omic positioning and the same biopharma and academic translational customer base.

Broad incumbents

• Bio-Techne: Bio-Techne operates the ProteinSimple (Ella, Simple Western) and Luminex multiplex assay franchises, serving translational and clinical research with multiplex protein detection. As a large life sciences tools incumbent with broad portfolio and established channels, it competes with Codetta's multi-omic positioning from a position of scale and reach.
• Bio-Rad Laboratories: Bio-Rad is a major life science tools incumbent and the historical leader in digital PCR (ddPCR/QX200). As a broad portfolio company with established translational and clinical research channels, it represents both a competitive force and a potential strategic acquirer for Codetta's dPCR-based multi-omic platform.
• Thermo Fisher Scientific: Thermo Fisher offers a broad portfolio spanning qPCR/dPCR instruments, immunoassays, and proteomics workflows (e.g., Orbitrap, TaqMan). As the dominant life science tools incumbent, it competes with Codetta through its scale, breadth, and channel reach, and represents a strategic acquirer for differentiated platform technologies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/codettabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Codetta Bio